Drug news
Soluble Ferric Pyrophosphate (Rockwell Medical) success in Phase III trial for Iron Deficiency
Rockwell Medical announced successful topline results from the PRIME clinical study of Soluble Ferric Pyrophosphate (SFP), its investigational iron-delivery drug currently in Phase III clinical studies for the treatment of Iron Deficiency in hemodialysis patients. The PRIME study demonstrated that regular administration of SFP-iron via dialysate reduced the usage of erythropoietin stimulating agents (ESAs) during hemodialysis by 37.1% while maintaining iron balance and maximizing iron delivery.